



ASX ANNOUNCEMENT: APPENDIX 4C

12 July 2019

The Manager
Company Announcements Office
ASX Limited, 20 Bridge St
SYDNEY NSW 2000

Dear Sir

APPENDIX 4C

Invion Limited (ASX:IVX) is pleased to lodge its Appendix 4C for the quarter ending 30 June 2019.

The Company held cash reserves of \$0.760 million at the end of June, with net cash inflows from operating activities during the quarter of \$0.284 million.

Receipts from customers, at \$1.903 million, was received for services under Invion's R&D services agreement with The Cho Group, a Hong Kong based group that funds and has successfully commercialised a number of unique and advanced technologies.

Subsequent to the end of the quarter, in accordance with the R&D services agreement, Invion invoiced The Cho Group in advance for activities anticipated to be undertaken in the September quarter.

During the June quarter, Invion announced that its research partner, the Hudson Institute of Medical Research, had completed initial in vivo experiments in animal models to examine the uptake, localisation and clearance from tumour tissue of Invion's photosensitiser, IVX-P02.

Dr Andrew Stephens, Group Head of the Ovarian Cancer Biomarkers Research Group at the Hudson Institute, said a highlight of the in vivo testing was the demonstrated uptake of IVX-P02 in circulating tumour cells (CTCs), which are cells that have shed from a primary tumour and are carried around the body in the blood.

Dr Stephens said the finding is significant because it suggests that IVX-P02 may have an application in the treatment of metastatic cancer, that is, cancer that has spread from the primary site of origin to different areas of the body.

An Appendix 4C accompanies this announcement.

For and on behalf of the Board of Invion Limited

MELANIE FARRIS
Company Secretary

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/3/00. Amended 30/9/01, 24/10/05, 17/12/10, 1/09/16

Name of entity

INVION LTD

ABN

76 094 730 417

Quarter ended ("current quarter")

30-June-2019

Consolidated statement of cash flows

	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	1,903	3,305
1.2 Payments for		
(a) research and development	(859)	(2,468)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(354)	(915)
(f) administration and corporate costs	(400)	(2,036)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	1
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	(6)	(6)
1.9 Net cash from/(used in) operating activities	284	(2,119)

2. Cash flows from investing activities

2.1 Payments to acquire:

- (a) property, plant and equipment
- (b) businesses (see item 10)
- (c) investments

-	-
-	-
-	-

Consolidated statement of cash flows	Current quarter	Year to date (12 months)
	\$A'000	\$A'000
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.2 Proceeds from disposal of:		-
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from/(used in) investing activities	-	-
3. Cash flows from financing activities		
3.1 Proceeds from issues of shares	-	-
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	-	-
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from/(used in) financing activities	-	-
4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	485	2,891
4.2 Net cash from / (used in) operating activities (item 1.9 above)	284	(2,119)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4 Net cash from / (used in) financing activities (item 3.10 above)	-	-

Consolidated statement of cash flows		Current quarter	Year to date (12 months)
		\$A'000	\$A'000
4.5	Effect of movement in exchange rates on cash held	(9)	(12)
4.6	Cash and cash equivalents at end of quarter	760	760

5. Reconciliation of cash and cash equivalents		Current quarter	Previous quarter
at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts		\$A'000	\$A'000
5.1	Bank Balances	760	485
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	760	485

6. Payments to directors of the entity and their associates		Current quarter
		\$A'000
6.1	Aggregate amount of payments to the parties included in item 1.2	(155)
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	

Payments to directors includes directors fees and executive directors salaries.

7. Payments to related entities of the entity and their associates		Current quarter
		\$A'000
7.1	Aggregate amount of payments to the parties included in item 1.2	-
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3	Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

8. Financing facilities available
Add notes as necessary for an understanding of the position

Total facility amount at quarter end \$A'000	Total drawn at quarter end \$A'000
-	-
-	-
-	-

- 8.1 Loan facilities
- 8.2 Credit standby arrangements
- 8.3 Other (please specify)

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

9. Estimated cash outflows for next quarter

- 9.1 Research and development
- 9.2 Product manufacturing and operating costs
- 9.3 Advertising and marketing
- 9.4 Leased assets
- 9.5 Staff costs
- 9.6 Administration and corporate costs
- 9.7 Other (provide details if material)
- 9.8 Total estimated cash outflows**

\$A'000
1,400
-
-
-
446
260
-
2,106

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)

- 10.1 Name of entity
- 10.2 Place of incorporation or registration
- 10.3 Consideration for acquisition or disposal
- 10.4 Total net assets
- 10.5 Nature of business

Acquisitions	Disposals
N/A	N/A

Compliance statement

¹ This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

² This statement gives a true and fair view of the matters disclosed.

Sign here: Original signed
(Company Secretary)



Date: 12-July-2019

Print name: Melanie Farris

Notes

¹ The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.

² If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

³ Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.